Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms

Prenatal Omega-6/Omega-3 Ratio and Attention Deficit and Hyperactivity Disorder Symptoms in Children: a Population-based Longitudinal Study

This study aimed to evaluate the longitudinal association between n-6:n-3 LCPUFAs ratio in cord blood and child ADHD symptoms at 4 and 7 years old. This study was based on the INMA project, a population-based birth cohort in Spain. Higher cord blood n-6:n-3 ratio was associated with higher subclinical ADHD symptoms during early and mid-childhood.

Study Overview

• Status: Completed
• Conditions: Attention Deficit Hyperactivity Disorder; Child Behavior Problem; Fatty Acid Deficiency

• Study Type: Observational
• Enrollment (Actual): 2644

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study was based on data from a population-based birth cohort, INMA (Infancia y Medio Ambiente [Environment and Childhood]) project, including four Spanish regions: Asturias (n=494) and Gipuzkoa (Basque Country) (n=638) on the Cantabrian coast, and Sabadell (Catalonia) (n=657) and Valencia (n=855) on the Mediterranean coast.

Description

Inclusion criteria:

• Age 16 years or older
• Singleton pregnancy
• No use of assisted reproductive techniques
• Intention to deliver at the reference hospital
• Ability to speak and understand Spanish or a local language

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Pregnant women

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Fatty acid ratio in cord blood	2004-2008
ADHD 4 years old	2008-2012
ADHD 7 years old	2012-2016

Collaborators and Investigators

• Sponsor: Barcelona Institute for Global Health

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2003
• Primary Completion (Actual): December 1, 2015
• Study Completion (Actual): December 1, 2015

Study Registration Dates

• First Submitted: September 13, 2017
• First Submitted That Met QC Criteria: September 13, 2017
• First Posted (Actual): September 14, 2017

Study Record Updates

• Last Update Posted (Actual): June 18, 2024
• Last Update Submitted That Met QC Criteria: June 17, 2024
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Nervous System Diseases; Neurologic Manifestations; Dyskinesias; Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Problem Behavior; Attention Deficit Disorder with Hyperactivity; Hyperkinesis
• Other Study ID Numbers: mlopez

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No